A new, automatic capsule filling system produced by Italian manufacturer MultiPharma is now available exclusively in the UK from Glenvale Packaging.
The MultiPharma V10 system is the first new machine to be introduced into the UK since Northamptonshire-based Glenvale Packaging was appointed to distribute MultiPharma’s products.
The totally enclosed V10 system is suitable for handling potent products and can process up to 9,000 capsules/hr. It has a footprint of 90x110cm and, owing to fitted castors, can be moved around a production facility.
‘The design is ideal for handling hard shell capsules – both gelatine and vegetarian options,’ said Garry Coleman, partner at Glenvale Packaging.
‘It is supplied fully specified to handle the desired capsule size. Additional accessories can then also be fitted to accommodate size changes as needed.’
The unit only requires air and electrical connections and is operated by a touchscreen that can be positioned to suit the operator’s needs. The anodised, aluminium construction meets GMP regulatory requirements.
‘The V10 has already been proven in Europe,’ added Coleman. ‘It is suited to a range of applications – from clinical trials in the health industry through to small manufacturing operations.’
Glenvale Packaging introduces MultiPharma V10 in the UK
An automatic capsule filling machine that handles potent products
You may also like
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model